Identifies and designs sgRNA sites for the engineered variants and orthogonal Cas9 nucleases. CasBLASTR allows to annotate CRISPR-Cas9 target sites for a given input sequence. This tool accepts several informations submitted by the user: the input sequence, the type of Cas9 protein, the 5' guide RNA design restrictions, and the desired spacer lengths. Concerning the data, the web tool offers a list of possible target sites which can be selected by the user from the table of outputs.
Molecular Pathology Unit & Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA USA; Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, MA, USA; Department of Pathology, Harvard Medical School, Boston, MA, USA; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Cardiovascular Research Center, Massachusetts General Hospital, Charlestown, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA,USA; Broad Institute, Cambridge, MA, USA
CasBLASTR funding source(s)
This work was supported by a National Institutes of Health (NIH) Director's Pioneer Award (DP1 GM105378), NIH R01 GM107427, NIH R01 GM088040, The Jim and Ann Orr Research Scholar Award, and a National Sciences and Engineering Research Council of Canada Postdoctoral Fellowship.